Journal List > Allergy Asthma Immunol Res > v.10(2) > 1095754

Choi, Kim, and Lee: Are Registration of Disease Codes for Adult Anaphylaxis Accurate in the Emergency Department?

Abstract

Purpose

There has been active research on anaphylaxis, but many study subjects are limited to patients registered with anaphylaxis codes. However, anaphylaxis codes tend to be underused. The aim of this study was to investigate the accuracy of anaphylaxis code registration and the clinical characteristics of accurate and inaccurate anaphylaxis registration in anaphylactic patients.

Methods

This retrospective study evaluated the medical records of adult patients who visited the university hospital emergency department between 2012 and 2016. The study subjects were divided into the groups with accurate and inaccurate anaphylaxis codes registered under anaphylaxis and other allergy-related codes and symptom-related codes, respectively.

Results

Among 211,486 patients, 618 (0.29%) had anaphylaxis. Of these, 161 and 457 were assigned to the accurate and inaccurate coding groups, respectively. The average age, transportation to the emergency department, past anaphylaxis history, cancer history, and the cause of anaphylaxis differed between the 2 groups. Cutaneous symptom manifested more frequently in the inaccurate coding group, while cardiovascular and neurologic symptoms were more frequently observed in the accurate group. Severe symptoms and non-alert consciousness were more common in the accurate group. Oxygen supply, intubation, and epinephrine were more commonly used as treatments for anaphylaxis in the accurate group. Anaphylactic patients with cardiovascular symptoms, severe symptoms, and epinephrine use were more likely to be accurately registered with anaphylaxis disease codes.

Conclusions

In case of anaphylaxis, more patients were registered inaccurately under other allergy-related codes and symptom-related codes rather than accurately under anaphylaxis disease codes. Cardiovascular symptoms, severe symptoms, and epinephrine treatment were factors associated with accurate registration with anaphylaxis disease codes in patients with anaphylaxis.

INTRODUCTION

Anaphylaxis is a serious, life-threatening generalized or systemic hypersensitivity reaction.123 Most anaphylaxis symptoms present acutely and worsen in a short period of time. For this reason, most anaphylactic patients report to the emergency department. Therefore, it is important for the medical staff of emergency department who first face anaphylactic patients to make an accurate diagnosis and provide an immediate and appropriate treatment. The incidence of anaphylaxis has been continuously rising worldwide over the past 20 years.45 The prevalence of anaphylaxis in the general population is at least 1.6% higher in the United States6 and ranged from 1.5 to 7.9 per 100,000 person-years in Europe.7 There has been active research on anaphylaxis, but many study subjects are limited to patients registered with anaphylaxis codes. As a result, patients not registered with anaphylaxis codes are excluded as study subjects.8 To accurately determine the rate of anaphylaxis, it is necessary to evaluate whether the symptoms and signs of patients meet the diagnostic criteria of anaphylaxis and to accurately register an anaphylaxis code. However, anaphylaxis codes tend to be underused,910 and are highly likely to be registered under anaphylaxis-associated codes, allergy-related disease codes, and symptom codes related to the symptoms and signs of anaphylaxis rather than under directly specified anaphylaxis codes. Therefore, if a large number of anaphylactic patients are registered under other codes and therefore excluded, accurate research on anaphylaxis incidence, etiology, and clinical characteristics may be affected.
To our knowledge, no previous report has assessed the incidence of anaphylactic patients registered under other codes than anaphylaxis. Therefore, this study determined the frequency and clinical characteristics of anaphylactic patients who met diagnostic criteria but were not registered under anaphylaxis codes in the emergency department by comparing them with those of patients who were accurately diagnosed with anaphylaxis.

MATERIALS AND METHODS

Study population

The subjects of this study included adult patients with anaphylaxis aged over 16 years who had presented to the emergency department of a tertiary hospital for 5 years between January 2012 and December 2016. Anaphylactic patients were defined based on a review of anaphylaxis frequency and characteristics and allergy-related codes.1112 To identify the omitted anaphylactic patients, disease codes related to symptoms and signs suggested in the clinical diagnostic criteria of anaphylaxis were also collected (Table 1).13 During the survey period, all medical records of the adult patients who were registered under the disease codes were reviewed retrospectively in order to re-evaluate whether they were actually diagnosed with anaphylaxis. Subjects were excluded if they did not meet the diagnostic criteria of anaphylaxis (as defined by the 2011 World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis) after reviewing all medical records for anaphylaxis, allergy-related, and symptom-related codes. The study subjects were divided into the accurate group which was registered under T78.0, T78.2, T78.2B, T78.2C, T80.5, and T88.6 codes with the direct specification of anaphylaxis and into the inaccurate coding group which was registered under allergy-related codes and symptom and sign related codes.
As the diagnostic criteria of anaphylaxis, the clinical criteria for diagnosing anaphylaxis suggested by 2011 World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis was applied.13
Anaphylaxis is highly likely when any one of the following 3 criteria is fulfilled.
1) Acute onset of an illness with involvement of the skin, mucosal tissue, or both and at least one of the following:
  1. Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, hypoxemia)

  2. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia [collapse], syncope, incontinence) or

2) Two or more of the following that occur rapidly after exposure to a likely allergen for that patient
  1. Involvement of the skin-mucosal tissue (e.g., generalized urticarial, itch-flush, swollen lips-tongue-uvula)

  2. Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, hypoxemia)

  3. Reduced blood pressure or associated symptoms (e.g., hypotonia [collapse], syncope, incontinence)

  4. Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting) or

3) Reduced blood pressure after exposure to known allergen for that patient
  1. Systolic blood pressure of less than 90 mmHg or greater than 30% decrease from that person's baseline

Data collection

Relevant materials were surveyed to evaluate the patients' general characteristics, causes of anaphylaxis, clinical characteristics, and treatments. We also collected demographic data including patient age, gender, transportation to the emergency department, elapsed time from exposure to symptom onset, elapsed time from symptom onset to emergency department arrival, history of allergic diseases, comorbidities, smoking status, and drinking status. Transportation to the emergency department was classified into public ambulance, transfer from another medical facility, and individual transportation. History of allergic diseases was classified into anaphylaxis, asthma, rhinitis, atopy, drugs, and foods. The causes of anaphylaxis were classified into drugs, radiocontrast media, insect stings, food, exercise, and idiopathic factors. For more detailed causes, drugs were categorized into nonsteroidal anti-inflammatory drugs, penicillin, cephalosporin, vaccines, and acetaminophen; insect stings were categorized into bee, ant, and other insects. Foods were classified into seafood, wheat, buckwheat, nuts, egg, and pork. Aside from those, exercise-induced causes, food-dependent exercise-induced causes, and idiopathic causes were also investigated. Regarding clinical manifestations, the patient symptoms were classified into skin and mucosal, respiratory, cardiovascular, gastrointestinal, and neurologic symptoms. In addition, the severity of hypersensitivity reactions, blood pressure at the time of emergency department arrival, and consciousness were surveyed. On the basis of the method reported by Brown,14 the severity of the hypersensitivity reactions was classified into severe and non-severe grades depending on hypoxia (SpO2 ≤92%), hypotension (systolic blood pressure <90 mmHg), and neurologic symptoms. Regarding prehospital treatment, the oxygen supply, fluid administration, and epinephrine administration were investigated. With regard to treatment in the emergency department, the oxygen supply, endotracheal intubation, fluid administration, steroid administration, epinephrine administration, bronchodilator administration, and cardiopulmonary resuscitation were investigated.

Statistical analysis

Frequency analyses of the registered codes were conducted in both the accurate and inaccurate coding groups. To compare the patients' general characteristics, causes of anaphylaxis, clinical manifestations, and treatments between the 2 groups, univariate comparison analysis was performed using χ2 test, Fisher's exact test, and Mann-Whitney U test. To identify the factors which were highly likely to be registered in the accurate group, those factors that had statistical significance were included in multivariate logistic regression analysis performed after correcting for patient gender. The statistical analyses were performed using IBM SPSS Statistics for Windows, version 21.0 (IBM Corp., Armonk, NY, USA). Statistical significance was defined as a P value less than 0.05.

Ethics statement

This study was exempted for review by the Institutional Review Board due to retrospective study.

RESULTS

During the 5-year study period, of 211,486 total adult patients who presented to the emergency department, we reviewed all medical records of 63,826 with International Statistical Classification of Diseases 10th Revision (ICD-10) codes that were associated with anaphylaxis, including anaphylaxis, allergy-related, and symptom-related codes. After excluding cases that did not meet the diagnostic criteria of anaphylaxis in each group, of 618 anaphylaxis patients, 161 (26.1%) and 457 (73.9%) were assigned to the accurate and inaccurate coding groups, respectively; 365 patients had allergy-related codes and 92 had symptom codes (Figure). The average ages were 48.0±13.3 and 44.2±14.2 years in the accurate and inaccurate coding groups, respectively. The 2 groups had no difference in gender. Regarding transportation to the emergency department, 68.3% of the accurate group and 88.8% of the inaccurate coding group had individual transportation. The inaccurate coding group had longer elapsed times from exposure to symptom onset and from symptom onset to emergency department arrival. With regard to past history of allergy, 7.5% of the accurate and 3.5% of the inaccurate coding groups had anaphylaxis history. Regarding comorbid diseases, 9.9% of the accurate and 3.7% of the inaccurate coding group had cancer history. The 2 groups had no differences in smoking history and alcohol consumption at the time of symptom onset (Table 2). Drugs were the cause of anaphylaxis, in 47.8% and 33.9% of the accurate and inaccurate coding groups, respectively. Analysis of the detailed causes revealed the differences between the 2 groups in cephalosporin (8.7% vs 4.4%), acetaminophen (5.0% vs 1.8%), and radiocontrast media (13.7% vs 2.0%). Insect stings accounted for 18.0% of the accurate group and 9.0% of the inaccurate coding group. Foods accounted for 26.1% and 42.5% of the accurate and inaccurate coding groups, respectively. The 2 groups had no difference in exercise. Idiopathic cases accounted for 6.8% of the accurate group and 12.5% of the inaccurate coding group (Table 3).
Among anaphylaxis symptoms, the accurate group had more cardiovascular (77.0% vs 34.8%) and neurologic (29.8% vs 9.8%) symptoms than the inaccurate coding group, whereas the inaccurate coding group had more cutaneous symptoms (92.3%) than the accurate group (74.5%). Severe symptoms occurred in 57.1% of the accurate group and 9.8% of the inaccurate coding group. Non-alert consciousness was present in 14.3% and 0.9% of the patients in the accurate and inaccurate coding groups, respectively. Regarding prehospital treatment, the accurate group more often had oxygen supply (4.3% vs 1.1%) and epinephrine use compared to the inaccurate coding group (2.5% and 0%). Regarding emergency department treatment, the accurate group had more oxygen supply (34.8% vs 9.8%), endotracheal intubation (4.3% vs 0%), and epinephrine use (57.8% vs 14.7%) than the inaccurate coding group. Fluid administration, steroid use, and bronchodilator use did not differ between the 2 groups (Table 4).
The factors with statistical significance in univariate comparison analysis were included in the multivariate logistic regression analysis after adjusting for gender. The results indicated that anaphylactic patients with cardiovascular symptoms, severe symptoms, and epinephrine use in the emergency department were likely to be registered with anaphylaxis codes (Table 5).

DISCUSSION

Anaphylaxis is a hypersensitivity reaction, ranging from urticaria to fatal systemic cardiovascular compromise. Its symptoms and signs vary and its causal relation with allergens is not clear. For this reason, relevant patients may be registered using other codes related to the symptoms and signs rather than anaphylaxis codes. Although anaphylaxis patients are registered under urticaria or angioedema symptom-related codes rather than anaphylaxis codes, any appropriate patient treatment is not incorrect. Nevertheless, registration of patients under other codes rather than anaphylaxis codes makes it difficult to accurately determine the anaphylaxis incidence. To our knowledge, there is no research on anaphylactic patients registered under other related codes. Therefore, future research on anaphylaxis should also consider inaccurately registered anaphylactic patients, as shown in this study.
In this study of patients who had presented to the emergency department for 5 years, 618 patients met the diagnostic criteria for anaphylaxis; of these, in the inaccurate coding group were registered under other codes than anaphylaxis codes, a number greater than that in the accurate group (161 patients). In the inaccurate coding group, the most common registered code was urticaria (173 patients), followed by angioedema (130 patients) (Figure). This finding indicates that skin features arising in urticaria and angioedema are easily observed with the naked eye. Additionally, compared to objective symptoms, subjective symptoms such as abdominal pain and shortness of breath are unclear or mild; therefore, patients meeting the diagnostic criteria were likely to be registered as having the subjective symptoms or angioedema, which are relatively clearer than anaphylaxis. In particular, if patients had clear skin features but other mild symptoms, they were often registered under urticaria. Patients with clear mucosal edema accompanied by respiratory symptom were often registered under angioedema. In the inaccurate coding group, 92 patients (14.9%) were registered under the codes in which the symptoms and signs are directly specified. The patient group registered under their respiratory symptom was the largest (31 patients), followed by skin and mucosal symptoms (29 patients). This is most likely because the medical staff was unable to accurately understand diagnostic criteria of anaphylaxis and to make a diagnosis; thus, the patients were registered under their chief complaint as a symptom code. Therefore, to accurately survey the anaphylaxis incidence rate, it is necessary to educate the medical staff of emergency departments to accurately understand the anaphylaxis diagnostic criteria.
Previous studies reported the principal triggers of anaphylaxis to include foods, insect stings, and drugs; however, there were differences depending on the study population, study design, and geographic area.4101516171819 In this study, the causes of anaphylaxis in the accurate group included drugs, foods, and insect stings in this order of prevalence, compared to foods, drugs, and idiopathic anaphylaxis in the inaccurate coding group. This result was similar to those of previous studies. In the accurate group, radiocontrast media were significantly large. That was because the administration of radiocontrast media in the course of examination in the emergency department triggered anaphylaxis and consequently there was a clear causal relation. In the inaccurate coding group, idiopathic anaphylaxis was significantly large.
Skin signs are the most characteristic symptoms and signs of anaphylaxis, frequently accompanied by respiratory, gastrointestinal, and cardiovascular symptoms.101620212223 In this study, cardiovascular signs, such as hypotension, were most common in the accurate group, followed by skin signs; in the inaccurate coding group, skin signs were most common, followed by respiratory symptoms. The reason for these differences was that the medical staff recognized patients with severe reactions like hypotension as having anaphylaxis and registered them using an anaphylaxis code; however, patients with relatively mild skin signs or mildly labored respiration were judged to meet the diagnostic criteria of anaphylaxis but were registered under other codes. This supports the finding that the accurate group had significantly higher frequencies of severe symptoms and non-alert consciousness.
Anaphylaxis is a medical emergency and prompt management is of vital importance. Epinephrine is an important drug for the initial management of anaphylaxis. Its delayed administration may lead to patient death.1324 This study also revealed that the accurate group had significantly higher use of oxygen supply and epinephrine administration. In particular, patients who were administered epinephrine were accurately registered with anaphylaxis codes 4.3 times more often than those who were not (Table 5). This difference means that patients who received epinephrine experienced severe reactions, such as hypotension or hypoxia. As described earlier, the medical staff clearly recognized these severe reactions as anaphylaxis and registered the patients with anaphylaxis codes. Medical practitioners in the emergency department tend to focus on patients with severe anaphylaxis who present with specific symptoms and treatment, as shown in this study. However, anaphylaxis can present with a wide range of symptom severity, from mild to fatal. No case of anaphylaxis should be overlooked, as anaphylaxis has a high probability of worsening within a short period. Therefore, it is important to continuously educate the medical staff in the emergency department about the manifestations and management of anaphylaxis. To accurately diagnose patients with mild symptoms and signs as anaphylactic patients, the medical staffs in the emergency department need to understand the diagnostic criteria of anaphylaxis and accurately register anaphylaxis codes. As shown in this study, there are cases where patients who met the diagnostic criteria of anaphylaxis were registered under other codes. Therefore, to identify anaphylactic patients, it is necessary to search for study patients including those registered with anaphylaxis-related codes.
The results of this study cannot be generalized as this was a retrospective study that was conducted at a single university hospital. Further prospective multicenter studies will be needed to overcome this limitation. The study subjects were only those patients who had reported to the hospital emergency department and did not include outpatients or patients who were hospitalized and had anaphylaxis. Given that anaphylaxis occurs acutely, the initial treatment is likely to be provided to the patients in the Emergency Department rather than outpatients, except for those who are hospitalized and have anaphylaxis. To search for anaphylactic patients, this study collected the disease codes used in previous works and symptom codes that satisfied the diagnostic criteria of anaphylaxis. Therefore, it is likely to have excluded anaphylactic patients who were registered with different disease codes. This study focused on the registered disease codes for anaphylactic patients in the emergency department of a single university hospital. The emergency department of a research hospital may have high or low registered disease codes for anaphylaxis, making it difficult to generalize the results of this study. Nevertheless, this study shows the potential for the underestimation of the anaphylaxis frequency and incidence rates reported in previous studies on anaphylaxis.
This study revealed that among adult anaphylactic patients who reported to the emergency department, those registered inaccurately outnumbered those registered accurately and that they were sometimes registered not only under allergy-related codes but also under symptom-related codes. Patients with cardiovascular symptoms, severe symptoms, and epinephrine use in the emergency department were highly likely to be accurately registered with anaphylaxis codes.

Notes

There are no financial or other issues that might lead to conflict of interest.

References

1. Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010; 125:S161–S181. PMID: 20176258.
crossref
2. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113:832–836. PMID: 15131563.
crossref
3. Lee SY, Ahn K, Kim J, Jang GC, Min TK, Yang HJ, et al. A multicenter retrospective case study of anaphylaxis triggers by age in Korean children. Allergy Asthma Immunol Res. 2016; 8:535–540. PMID: 27582405.
crossref
4. Ben-Shoshan M, Clarke AE. Anaphylaxis: past, present and future. Allergy. 2011; 66:1–14.
crossref
5. Lieberman P, Camargo CA Jr, Bohlke K, Jick H, Miller RL, Sheikh A, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006; 97:596–602. PMID: 17165265.
crossref
6. Wood RA, Camargo CA Jr, Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014; 133:461–467. PMID: 24144575.
crossref
7. Panesar SS, Javad S, de Silva D, Nwaru BI, Hickstein L, Muraro A, et al. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy. 2013; 68:1353–1361. PMID: 24117770.
crossref
8. Simons FE, Sampson HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol. 2008; 122:1166–1168. PMID: 19084110.
crossref
9. Sampson HA, Muñoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005; 115:584–591. PMID: 15753908.
crossref
10. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006; 117:391–397. PMID: 16461139.
crossref
11. Rudders SA, Banerji A, Corel B, Clark S, Camargo CA Jr. Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics. 2010; 125:e711–e718. PMID: 20308215.
crossref
12. Roh EJ, Chung EH, Lee MH, Lee SJ, Youn YS, Lee JH, et al. Clinical features of anaphylaxis in the middle area of South Korea. Pediatr Allergy Respir Dis. 2008; 18:61–69.
13. Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011; 4:13–37. PMID: 23268454.
crossref
14. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004; 114:371–376. PMID: 15316518.
crossref
15. Ye YM, Kim MK, Kang HR, Kim TB, Sohn SW, Koh YI, et al. Predictors of the severity and serious outcomes of anaphylaxis in Korean adults: a multicenter retrospective case study. Allergy Asthma Immunol Res. 2015; 7:22–29. PMID: 25553259.
crossref
16. Yang MS, Lee SH, Kim TW, Kwon JW, Lee SM, Kim SH, et al. Epidemiologic and clinical features of anaphylaxis in Korea. Ann Allergy Asthma Immunol. 2008; 100:31–36. PMID: 18254479.
crossref
17. Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL, Weaver A, et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol. 2008; 122:1161–1165. PMID: 18992928.
crossref
18. Tham EH, Tay SY, Lim DL, Shek LP, Goh AE, Giam YC, et al. Epinephrine auto-injector prescriptions as a reflection of the pattern of anaphylaxis in an Asian population. Allergy Asthma Proc. 2008; 29:211–215. PMID: 18430320.
crossref
19. Anaphylaxis Working Party. Australasian Society of Clinical Immunology and Allergy. Gold MS. EpiPen epidemic or good clinical practice? J Paediatr Child Health. 2003; 39:376–377. PMID: 12887670.
crossref
20. Brown SG, Mullins RJ, Gold MS. Anaphylaxis: diagnosis and management. Med J Aust. 2006; 185:283–289. PMID: 16948628.
21. Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010; 126:477–480. –480.e1. –480.e42. PMID: 20692689.
crossref
22. Yocum MW, Butterfield JH, Klein JS, Volcheck GW, Schroeder DR, Silverstein MD. Epidemiology of anaphylaxis in Olmsted County: a population-based study. J Allergy Clin Immunol. 1999; 104:452–456. PMID: 10452770.
crossref
23. Jiang N, Yin J, Wen L, Li H. Characteristics of anaphylaxis in 907 chinese patients referred to a tertiary allergy center: a retrospective study of 1,952 episodes. Allergy Asthma Immunol Res. 2016; 8:353–361. PMID: 27126729.
crossref
24. Brockow K, Christiansen C, Kanny G, Clément O, Barbaud A, Bircher A, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy. 2005; 60:150–158. PMID: 15647034.
crossref
Figure

The numbers of accurately and inaccurately registered anaphylaxis patients. We excluded patients (a) without ICD-10 codes that are associated with anaphylaxis (anaphylaxis, anaphylaxis-related, and symptom-related codes). We further excluded (b) patients with allergy- and symptom-related codes who did not satisfy the diagnostic criteria of anaphylaxis patients among those with ICD-10 codes associated with anaphylaxis.

aair-10-137-g001
Table 1

International Statistical Classification of Diseases 10th Revision (ICD-10) codes associated with anaphylaxis

aair-10-137-i001
Codes ICD-10 codes
Anaphylaxis codes
 Anaphylaxis T78.2B, T78.2C
 Anaphylactic shock T78.0, T78.2, T80.5, T88.6
Allergy-related codes
 Asthma J45.0, J45.1, J45.8, J45.9, J46
 Urticaria L28.2C, L50.0, L50.1, L50.8, L50.9
 Angioedema T78.3
 Food allergy T78.1
 Allergy T78.4, T78.4A, T78.4B
 Drug allergy T88.7, T88.7B, T88.7C, T88.7D, T88.7E, Z88
 Insect stings S-codes, T00.9F, T14.0G, T14.1A, T63.4, T63.4A, W57, X23
Symptom and sign codes
 Skin and mucosal
  Laryngeal edema J38.48, J38.49
  Itch L29.9
  Rash, flushing R21, R23.2
  Edema R60.0, R60.1, R60.9
 Respiratory
  Cough R05
  Dyspnea, cyanosis R06.0, R23.0
  Stridor, wheezing R06.1, R06.2
 Cardiovascular
  Cardiac arrest I46.0, I46.9
  Hypotension I95.0, I95.1, I95.2, I95.8, I95.9
  Chest pain R07.1, R07.3, R07.4
  Syncope R55.0, R55.8
  Shock R57.8, R57.9
 Gastrointestinal
  Abdominal pain R10.1, R10.3, R10.4
  Nausea, vomiting R11.1, R11.2, R11.3
  Incontinence R15, R32
 Neurologic
  Confusion R41.0
  Dizziness R42
  Headache R51
  Seizure R56.8
Table 2

General characteristics of accurate and inaccurate anaphylaxis registration

aair-10-137-i002
Variables Accurate (n=161) Inaccurate coding (n=457) P
Average age (year) 48.0±13.3 44.2±14.2 0.003*
Sex, male 89 (55.3) 229 (50.1) 0.259
Transportation to ED 0.000
 Public ambulance 32 (19.9) 37 (8.1)
 Other medical facility 19 (11.8) 14 (3.1)
 Individual transportation 110 (68.3) 406 (88.8)
Elapsed time from (minute)
 Exposure to symptom onset 10 (0–30) 30 (1–95) 0.010
 Symptom onset to ED arrival 60 (30–120) 60 (40–300) 0.000
Past history of allergy 71 (44.1) 199 (43.5) 0.273
 Anaphylaxis 12 (7.5) 16 (3.5) 0.038
 Asthma 7 (4.3) 10 (2.2) 0.164
 Allergic rhinitis 4 (2.5) 19 (4.2) 0.335
 Atopic dermatitis 2 (1.2) 10 (2.2) 0.740
 Drug 19 (11.8) 56 (12.3) 0.880
 Food 27 (16.8) 73 (16.0) 0.813
Comorbid diseases
 DM 13 (8.1) 29 (6.3) 0.454
 Hypertension 27 (16.8) 54 (11.8) 0.109
 Ischemic heart disease 7 (4.3) 12 (2.6) 0.276
 Cancer 16 (9.9) 17 (3.7) 0.003
Alcohol ingestion, case No./total No. 8/112 (7.1) 18/235 (7.7) 0.864
Smoking, case No./total No. 21/72 (29.2) 27/142 (19.0) 0.212

Values are presented as mean±standard deviation, median (interquartile range), or number (%).

ED, emergency department; DM, diabetes mellitus.

Univariate comparison analysis was performed using *Student's t test; Mann-Whitney U test; Fisher's exact test.

Table 3

Causes of accurate and inaccurate anaphylaxis registration

aair-10-137-i003
Variables Accurate (n=161) Inaccurate coding (n=457) P
Drug 55 (34.2) 146 (31.9)
 NSAIDs 27 (16.8) 53 (11.6) 0.093
 Penicillin 4 (2.5) 12 (2.6) 1.000*
 Cephalosporin 14 (8.7) 20 (4.4) 0.039
 Acetaminophen 8 (5.0) 8 (1.8) 0.040*
Radiocontrast 22 (13.7) 9 (2.0) 0.000
Insect sting 29 (18.0) 41 (9.0)
 Bee 28 (17.4) 34 (7.4) 0.000
Food 42 (26.1) 194 (42.5)
 Sea food 13 (8.1) 89 (19.5) 0.001
 Wheat 2 (1.2) 9 (2.0) 0.737*
 Peanut 1 (0.6) 7 (1.5) 0.687*
 Pork 2 (1.2) 14 (3.1) 0.262*
Exercise without food 3 (1.9) 3 (0.7) 0.185*
Exercise with food 0 (0.0) 3 (0.7) 0.571*
Idiopathic 11 (6.8) 57 (12.5) 0.049

Values are presented as number (%).

NSAID, nonsteroidal anti-inflammatory drug.

*Fisher's exact test.

Table 4

Clinical characteristics of accurate and inaccurate anaphylaxis registration

aair-10-137-i004
Characteristics Accurate (n=161) Inaccurate coding (n=457) P
Symptoms
 Cutaneous 120 (74.5) 422 (92.3) 0.000
 Respiratory 114 (70.8) 312 (68.3) 0.550
 Cardiovascular 124 (77.0) 159 (34.8) 0.000
 Gastrointestinal 27 (16.8) 128 (28.0) 0.005
 Neurologic 48 (29.8) 45 (9.8) 0.000
Blood pressure (mmHg)
 Systolic blood pressure 120.0 (89–142) 134.0 (119–149) 0.000
 Diastolic blood pressure 70.0 (56.5–85.0) 80.0 (71.5–92.0) 0.000
Severe symptoms 92 (57.1) 45 (9.8) 0.000
Non-alert consciousness 23 (14.3) 4 (0.9) 0.000
Pre-hospital treatment
 Oxygen supply 7 (4.3) 5 (1.1) 0.017*
 Epinephrine use 4 (2.5) 0 (0.0) 0.004*
ED treatment
 Oxygen supply 56 (34.8) 45 (9.8) 0.000
Endotracheal intubation 7 (4.3) 0 (0.0) 0.000*
 Fluid administration 159 (98.8) 440 (95.4) 0.053
 Steroid use 150 (93.2) 407 (89.1) 0.133
 Epinephrine use 93 (57.8) 67 (14.7) 0.000
 Bronchodilator use 29 (18.0) 63 (13.8) 0.195
 Cardiopulmonary resuscitation 3 (1.9) 0 (0.0) 0.017*

Values are presented as median (interquartile range) or number (%).

ED, emergency department.

*Fisher's exact test.

Table 5

Factors associated with disease codes for accurate anaphylaxis registration

aair-10-137-i005
Characteristics Odds ratio 95% confidence interval P
Cardiovascular symptom 2.705 1.667–4.390 0.000
Severe symptom 5.481 3.335–9.007 0.000
Epinephrine use in ED 4.334 2.737–6.864 0.000

ED, emergency department.

TOOLS
Similar articles